Renal stone disease, hypercalciuria, and osteoporosis: Use of thiazides and alkali for osteoporosis

Research output: Chapter in Book/Report/Conference proceedingChapter


Osteoporosis and nephrolithiasis are two common and overlapping medical conditions. A number of pathophysiologic mechanisms that lead to excessive urinary calcium excretion may contribute to decreased bone mass and greater fracture risk in kidney stone formers and patients with osteoporosis. In selected patients with low bone mass, treatment of hypercalciuria with thiazide diuretics and/or alkali therapy may improve bone mineral density and reduce fracture risk beyond what can be achieved with typical antiosteoporosis drugs. Thiazide diuretics may improve bone health indirectly by reducing urinary calcium excretion, but direct effects on osteoclasts and osteoblasts may contribute to the reduction in fracture risk with these agents. This chapter reviews the epidemiology, pathophysiologic mechanisms, evaluation, and management of hypercalciuria in patients with osteoporosis.

Original languageEnglish (US)
Title of host publicationMarcus and Feldman’s Osteoporosis
Number of pages20
ISBN (Electronic)9780128130735
StatePublished - Jan 1 2020


  • Alkali
  • Hypercalciuria
  • Nephrolithiasis
  • Osteoporosis
  • Thiazides

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)


Dive into the research topics of 'Renal stone disease, hypercalciuria, and osteoporosis: Use of thiazides and alkali for osteoporosis'. Together they form a unique fingerprint.

Cite this